BDRX Biodexa Pharmaceuticals Plc
Price Chart
Executive Summary
Biodexa Pharmaceuticals filed its 6-K on May 14, 2026, announcing its Annual General Meeting (AGM) scheduled for June 17, 2026, and proposing a share capital reorganization. The reorganization involves a 10,000-for-1 reverse stock split followed by a subdivision, creating a new class of 'E deferred shares' with negligible rights, while maintaining the same number of ADSs outstanding and proportionate ownership. The filing also seeks shareholder authority to allot new shares up to an aggregate nominal value of £25,000,000 and to disapply pre-emption rights, providing flexibility for future acquisitions and financings. This is a routine administrative event with no material financial impact, as the reorganization is designed to simplify the capital structure without altering shareholder value.
Actionable Insight
Monitor the AGM vote outcome on June 17, 2026; passage of the share reorganization is expected and should not affect the stock price. The authority to issue new shares up to £25M nominal value provides flexibility for future dilutive events—watch for subsequent offerings or acquisition announcements.
Key Facts
- AGM scheduled for June 17, 2026, to vote on share capital reorganization and other resolutions.
- Proposed consolidation of every 10,000 existing ordinary shares into one new ordinary share, followed by a subdivision and creation of E deferred shares.
- Outstanding shares as of May 6, 2026: 373,056,808,922 ordinary shares, equivalent to approximately 746,113 ADSs.
- The reorganization will not change the number of ADSs outstanding or shareholders' proportionate ownership.
- Directors seek authority to allot shares up to an aggregate nominal value of £25,000,000 and to disapply pre-emption rights, expiring at the 2029 AGM.
- Board unanimously recommends voting in favor of all resolutions.
Financial Impact
No direct financial impact; the reorganization is administrative and does not alter shareholder value or ADS count.
Risk Factors
- Potential future dilution if the board exercises the authority to allot new shares for acquisitions or financing.
- Fractional share entitlements from the consolidation may result in small cash distributions or forfeiture for holders of fewer than 10,000 shares.
Market Snapshot
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001214659-26-006195 |
| Exhibit: ex99_1.htm | 0001214659-26-006195 |
| Exhibit: ex99_6.htm | 0001214659-26-006195 |
| Exhibit: ex99_5.htm | 0001214659-26-006195 |
| Exhibit: ex99_4.htm | 0001214659-26-006195 |
| Document: w5122626k.htm | 0001214659-26-006195 |
| Document: 0001214659-26-006195-index-headers.html | 0001214659-26-006195 |
| Document: 0001214659-26-006195-index.html | 0001214659-26-006195 |
| Document: 0001214659-26-006195.txt | 0001214659-26-006195 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 14, 2026
4w ago
|
6-K
| $3.30 $3.28 | ▼ −0.61% | ▼ −1.57% | $3.03 (−8.18%) |
|
Mar 31, 2026
10w ago
|
EFFECT
| $3.09 $3.51 | ▼ −13.59% | ▼ −9.65% | $3.03 (+1.94%) |
|
Mar 23, 2026
11w ago
|
Press Release
| $3.42 $3.06 | ▼ −10.53% | ▼ −6.96% | $3.03 (−11.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access